Aytu BioPharma Inc (AYTU)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$2.21-3.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AYTU
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2013 | Jun 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 56.6 | 66.4 | 81.0 | 107.4 | 96.7 | 65.6 | 27.6 | 3.7 | 3.2 | 2.6 | 0.3 | — | — |
| Total Revenues | — | — | — | — | — | — | 27.6 | 3.7 | 3.2 | 2.6 | 0.3 | — | — |
| Cost of Revenues | 19.9 | 20.6 | 26.4 | 40.8 | 44.4 | 36.4 | 8.3 | 2.1 | 1.4 | 1.0 | 0.1 | — | — |
| Gross Profit | 36.7 | 45.8 | 54.6 | 66.6 | 52.3 | 29.2 | 19.4 | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | 34.8 | 17.7 | 17.4 | 8.5 | — | — | — |
| R&D Expenses | — | 1.3 | 2.8 | 4.1 | 12.7 | 5.6 | 1.7 | 0.2 | 1.0 | 6.1 | 3.2 | — | — |
| Operating Income | (15.2) | (7.8) | (5.3) | (17.1) | (109.9) | (58.9) | (21.1) | (19.7) | (20.1) | (21.7) | (7.6) | (0.1) | (0.1) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 3.7 | 4.8 | — | — | — | 2.6 | 0.7 | 2.5 | 5.5 | — | 0.0 | 0.0 |
| Other Non-Operating Income / Expenses | — | — | — | 0.0 | 1.0 | 0.8 | 7.5 | 9.5 | (2.4) | (6.5) | — | (0.0) | (0.0) |
| Asset Writedown | — | 8.3 | — | 5.7 | 75.5 | 12.8 | 0.2 | 1.9 | 1.3 | 7.5 | — | — | — |
| EBT, Incl. Unusual Items | (33.7) | (13.7) | (14.1) | (17.1) | (108.9) | (58.0) | (13.6) | — | — | (28.2) | (7.7) | — | — |
| Income Tax Expense | — | 0.4 | 1.8 | 0.0 | (0.1) | 0.3 | 0.0 | — | 0.0 | 0.0 | (0.0) | — | — |
| Net Income | |||||||||||||
| Net Income | (34.1) | (13.6) | (15.8) | (17.1) | (108.8) | (58.3) | (13.6) | (10.2) | (22.5) | (28.2) | (7.7) | (0.1) | (0.1) |
| Per Share | |||||||||||||
| Basic EPS | (3.24) | (2.16) | (2.86) | (5.11) | (74.01) | (3.48) | — | — | — | — | — | — | — |
| Diluted EPS | (3.24) | — | — | (5.11) | (74.01) | (3.48) | — | — | — | — | — | — | — |
| Revenue per Share | 5.38 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 10.5 | 6.3 | 5.5 | 3.3 | 1.5 | 16.7 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 10.5 | — | — | 3.3 | 1.5 | 16.7 | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (2.5) | 2.2 | (9.7) | (100.5) | (49.7) | (21.0) | (19.4) | (15.8) | (20.8) | (7.5) | 0.0 | — |
| EBIT | (15.2) | (7.8) | (5.3) | (17.1) | (109.9) | (58.9) | (21.1) | (19.7) | (20.1) | (21.7) | (7.6) | (0.1) | (0.1) |
| Effective Tax Rate | — | — | — | 0.0% | 0.1% | -0.4% | 0.0% | — | — | 0.0% | 0.3% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.